The Dubai royal’s investment approach through Inmā Emirates Holdings demonstrates how patient capital and technology transfer can generate measurable social impact across emerging markets By Exec Edge Editorial Staff The language of impact investing has evolved from philanthropic experiment to...

By Karen Roman SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing. In response to a competitor’s study comparing its own test...

Download the Complete Report Here By Brandon Hornback Seeking a stock-market bargain to brighten the holidays? Savvy investors should consider a single equity that captures the best of the burgeoning Telegram ecosystem, cryptocurrency at a discount and top-notch AI assets,...

IPO Edge hosted a fireside chat on Dec. 9 from the floor of the New York Stock Exchange during the Bloomberg Activism Forum 2025 with Steve Parish, Managing Partner, Equity Capital Markets at ICR Capital. The in-person interview was joined by...

Download the Complete Report Here By Brandon Hornback SOL Strategies Inc. (NASDAQ: STKE) is the premiere play on Solana’s (SOL) accelerated growth, packaged as an easily-accessible public equity. After a broad-based selloff in shares of digital asset treasury (DAT) companies,STKE...

By Exec Edge Editorial Staff Vinson & Elkins advised Coterra Energy Inc. on a behind-the-meter power purchase agreement with PROPWR, a subsidiary of ProPetro Holding Corp., to develop a distributed microgrid at Coterra’s production sites in the New Mexico portion...

Download the Complete Report Here By Brandon Hornback REX American Resources Corp. (NYSE: REX) continued its long-running winning of streak, making it 21 straight profitable quarters. Ethanol volumes edged higher and operational discipline helped offset softer pricing, reinforcing REX’s position...

By Karen Roman Sequana Medical NV (BRU: SEQUA.BR) said it successfully implanted the alfapump device for treatment of recurrent or refractory ascites due to liver cirrhosis in two patients at the University of Pennsylvania. The alfapump is the first FDA-approved...

By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...

Exec Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Chris Searles, co-founder and Chief Executive Officer, and Trevor Smith, co-founder and Chief Technology Officer of DxCheck. The in-person interview was joined by Editor-in-Chief John Jannarone and...